Analysts first point out that, unlike other European companies impacted by the ongoing conflict in the Middle East, diagnostic testing firms remain relatively shielded. Their services are non-discretionary in nature: hospitals and laboratories, for instance, cannot scale back operations even during crises. Furthermore, the Middle East accounts for only a small fraction of their total revenue.

Drivers of the share price decline

The research firm notes that since its last study in July 2025, the stock has come under heavy pressure, falling by approximately 20%. Several factors explain this underperformance, but the primary catalyst was the repeated downward revision of 2025 guidance. Other headwinds included low viral circulation in North America and the EMEA region (Europe, Middle East, and Africa), which led to disappointing sales for Biofire respiratory panels. Meanwhile, the Chinese market faced pricing pressure from centralized procurement tenders and weakened demand due to unfavorable budgetary trends in the healthcare sector. Currency headwinds further exacerbated the situation.

bioMérieux outperforming the competition

Nevertheless, AlphaValue highlights that bioMérieux outperformed its peers last year with organic growth of 6.2%. Competitors such as Qiagen and DiaSorin posted growth of 5% and 4%, respectively. Analysts also observed improved profitability, with operating income rising 16.1% at constant exchange rates. The 2026 targets are aligned with the GO28 strategic plan and exceed those of the competition. The group is targeting organic growth between 5% and 7% and an increase in operating income of at least 10%.

Technological leadership

Finally, AlphaValue identifies the group's "undisputed" technological leadership as another key asset. The company holds a 75% market share in "high-plex" molecular diagnostics (multiple analyses on a single sample) through its Biofire platform. The latter covers over 170 pathogens, compared to approximately 100 for competitors. This comprehensiveness enables faster diagnoses, reduces unnecessary antibiotic use, and limits the need for supplemental testing.

However, analysts warn that DiaSorin's introduction of a "per-selected pathogen" pricing model—where customers only pay for the specific agents they wish to test—could become a differentiating factor in the medium term against bioMérieux's fixed-panel model.
Regarding the business model, AlphaValue describes it as "resilient." Once equipment is installed, the company generates recurring revenue through reagents and cartridges. Analysts estimate that 80% to 90% of sales are recurring. Furthermore, the complexity and replacement cost of the instruments ensure long-term customer loyalty.

In conclusion, AlphaValue believes the bioMérieux investment case is one for patient investors. Growth expectations have shifted from "alluring" to "healthy." As for the balance sheet, it appears robust; the 9% dividend hike last year indicates no financial distress. The recommendation remains a Buy with a six-month price target of 123 euros, representing a 37.5% upside potential.